2015 Research Articles
Overview
Causes/Risk Factors
Associated Diseases
Treatment: Herbal Antibiotics
Antibiotic Treatment: Rifaximin
Microbiome
Low FODMAP Diet
- Current views on the etiopathogenesis, clinical manifestation, diagnostics, treatment and correlation with other nosological entities of SIBO. PMID:25657082
- Small intestinal bacterial overgrowth syndrome in children. PMID:25960812
- Small Bowel Bacterial Overgrowth in Children: A Comprehensive Review. PMID:26196206
- SIBO: Dysbiosis Has A New Name
Causes/Risk Factors
- Autoimmunity Links Vinculin to the Pathophysiology of Chronic Functional Bowel Changes Following Campylobacter jejuni Infection in a Rat Model. PMID: 25424202
- Small Bowel Bacterial Overgrowth Associated with Persistence of Abdominal Symptoms in Children Treated with a Proton Pump Inhibitor. PMID:25681195
- Duodenal Aspirates for Small Intestine Bacterial Overgrowth: Yield, PPIs, and Outcomes after Treatment at a Tertiary Academic Medical Center. PMID:25694782
- What are the effects of proton pump inhibitors on the small intestine? PMID:26078557
- Association between chronic use of proton pump inhibitors and small- intestinal bacterial overgrowth assessed using lactulose hydrogen breath tests. PMID:25916046
- Jejunal diverticulosis found in a patient with long-standing pneumoperitoneum and pseudo-obstruction on imaging: a case report. PMID:26220890
- [Prevalence of gastrointestinal disorders in adults with common variable immunodeficiency at Specialty Hospital Dr. Bernardo Sepulveda]. PMID:25758107
Associated Diseases
- Helicobacter pylori infection but not small intestinal bacterial overgrowth may play a pathogenic role in rosacea. PMID:25653855
- The biopsy pathology of non-coeliac enteropathy. PMID:25234408
- Management of pediatric intestinal failure. PMID:25752806
- An insight into the gastrointestinal component of fibromyalgia: clinical manifestations and potential underlying mechanisms. PMID:25119830
- Molecular assessment of differences in the duodenal microbiome in subjects with irritable bowel syndrome. PMID:25865706
- Possible underestimation of SIBO in IBS patients: is lack of Glucose Breath Test standardization responsible? PMID:26220649
- Potential Causes and Present Pharmacotherapy of Irritable Bowel Syndrome: An Overview. PMID:26139425
- Small intestinal bacterial overgrowth prevalence in celiac disease patients is similar in healthy subjects and lower in irritable bowel syndrome patients. PMID:26070374
- Irritable Bowel Syndrome and the Small Intestinal Microflora. What Do We Know? PMID:26076568
- Small bowel bacterial overgrowth in patients with irritable bowel syndrome: the first study in iran. PMID:25628852
- The therapeutic management of gut barrier leaking: the emerging role for mucosal barrier protectors. PMID:25855934
- [Small intestinal bacterial overgrowth as a cause of lactase deficiency]. PMID:25864343
- Carbohydrate Malabsorption and Putative Carbohydrate-Specific Small Intestinal Bacterial Overgrowth: Prevalence and Diagnostic Overlap Observed in an Austrian Outpatient Center. PMID:26138365
- Breath hydrogen and methane are associated with intestinal symptoms in patients with chronic pancreatitis. PMID:26278025
- Intestinal mucosal barrier dysfunction participates in the progress of nonalcoholic fatty liver disease. PMID:26097546
- Effects of SIBO and rifaximin therapy on MHE caused by hepatic cirrhosis. PMID:25932262
- Small intestinal bacterial overgrowth and toll like receptor signaling in patients with nonalcoholic fatty liver disease. PMID:26212089
- Management of pancreatic, gastrointestinal and liver complications in adult cystic fibrosis. PMID:26001957
- Glucose breath test and Crohn's disease: Diagnosis of small intestinal bacterial overgrowth and evaluation of therapeutic response. PMID:25990116
- Clinical Significance of the Glucose Breath Test in Patients with Inflammatory Bowel Disease. PMID:25612007
- Environmental enteric dysfunction: an overview. PMID:25902619
- Prospective Study of Malabsorption and Malnutrition After Esophageal and Gastric Cancer Surgery. PMID:26583669
- Small intestinal bacterial overgrowth in patients with refractory functional gastrointestinal disorders. PMID:26554916
- Macronutrient intakes in obese subjects with or without small intestinal bacterial overgrowth: an alimentary survey. PMID:26375876
- The treatment of gastroparesis, constipation and small intestinal bacterial overgrowth syndrome in patients with Parkinson's disease. PMID:26374094
- Small Intestinal Bacterial Overgrowth Diagnosed by Glucose Hydrogen Breath Test in Post-cholecystectomy Patients. PMID:26351251
- What tests should you use to assess small intestinal bacterial overgrowth in systemic sclerosis? PMID:26339892
- Fecal calprotectin in systemic sclerosis and review of the literature. PMID:25661980
- Development and validation of a biomarker for diarrhea-predominant irritable bowel syndrome in human subjects. PMID: 25970536
- Inclusion Of A Novel Ibs Blood Panel For Diagnosing Diarrhea Predominant Irritable Bowel Syndrome (Ibs-D): A Uk Perspective. PMID:26531982
- A Novel Ibs Diagnostic Blood Panel Can Enhance A Positive Diagnostic Strategy Versus A Strategy Of Exclusion For Patients With Diarrhea Predominant Irritable Bowel Syndrome (Ibs-D): Cost Implications For Denmark. PMID: 26531981
- Cost-Minimization For A Novel Ibs Diagnostic Blood Panel Versus Standard Exclusionary Diagnostic Testing For Diarrhea Predominant Irritable Bowel Syndrome: A United States Perspective. PMID:26531980
- Impact Of A Novel Ibs Diagnostic Blood Panel For Mexico: Cost Implications To The Mexican Private Practice For Diarrhea Predominant Irritable Bowel Syndrome (Ibs-D). PMID:26531979
- Potential For Cost Savings Associated With A Novel Ibs Blood Panel For Diagnosing Diarrhea Predominant Irritable Bowel Syndrome (Ibs-D): Italian Perspective. PMID:26531976
- Small intestinal bacterial overgrowth: duodenal aspiration vs glucose breath test. PMID:25600077
- Diagnostic modalities for the evaluation of small bowel disorders. PMID:25635667
- Possible underestimation of SIBO in IBS patients: is lack of Glucose Breath Test standardization responsible? PMID:26220649
- Predisposing factors for positive D-Xylose breath test for evaluation of small intestinal bacterial overgrowth: a retrospective study of 932 patients. PMID:25914466
- Fecal calprotectin in systemic sclerosis and review of the literature. PMID:25661980
- What tests should you use to assess small intestinal bacterial overgrowth in systemic sclerosis? PMID:26339892
- Duodenal Aspirates for Small Intestine Bacterial Overgrowth: Yield, PPIs, and Outcomes after Treatment at a Tertiary Academic Medical Center. PMID:25694782
- Additional Value of CH₄ Measurement in a Combined (13)C/H₂ Lactose Malabsorption Breath Test: A Retrospective Analysis. PMID:26371034
- Predicting a Response to Antibiotics in Patients with the Irritable Bowel Syndrome. PMID:26362282
- Scintigraphy Demonstrates High Rate of False-positive Results From Glucose Breath Tests for Small Bowel Bacterial Overgrowth. PMID:26241509
- Healthy control subjects are poorly defined in case-control studies of irritable bowel syndrome. PMID: 25609236
- Measurement of oro-caecal transit time by magnetic resonance imaging. PMID: 25576231 DOI: 10.1007/s00330-014-3575-1
- Pilot Study on Gas Patterns of Irritable Bowel Syndrome and Small Intestinal Bacterial Overgrowth Following Ingestion of Lactulose. doi: 10.4236/ojgas.2015.511025.
Treatment: Herbal Antibiotics
Antibiotic Treatment: Rifaximin
- Rifaximin for the treatment of diarrhoea-predominant irritable bowel syndrome. PMID:25641072
- Determination of rifaximin treatment period according to lactulose breath test values in nonconstipated irritable bowel syndrome subjects. PMID:26028929
- Profile of rifaximin and its potential in the treatment of irritable bowel syndrome. PMID:26089696
- Susceptibility to rifaximin and other antimicrobial agents of bacteria isolated from acute gastrointestinal infections in Mexico. PMID:26525276
- Rifaximin (Xifaxan) for irritable bowel syndrome with diarrhea. PMID:26218792
- Rifaximin: the revolutionary antibiotic approach for Irritable Bowel Syndrome. PMID:26202193
- Rifaximin: An Antibiotic with Important Biologic Effects. PMID:26202192
- Central and mucosal immunity are modified by non absorbable antibiotics treatment in uncomplicated diverticular disease. PMID:26202195
- Understanding the molecular mechanisms of rifaximin in the treatment of gastrointestinal disorders - a focus on the modulation of host tissue function. PMID:26202186
- Therapeutic Effects and Mechanisms of Action of Rifaximin in Gastrointestinal Diseases. PMID:26162610
- Rifaximin and Eluxadoline - Newly Approved Treatments for Diarrhea-Predominant Irritable Bowel Syndrome: What is Their Role in Clinical Practice Alongside Alosetron? PMID:26559529
- Current and emerging drug options in the treatment of diarrhea predominant irritable bowel syndrome. PMID:26558923
- Management of opioid-induced constipation for people in palliative care. PMID:26126675
- Long term outcome of Prucalopride for chronic constipation: a single centre study. PMID:25951504
- New pharmacological treatment options for irritable bowel syndrome with constipation. PMID:26548544
Microbiome
- Molecular assessment of differences in the duodenal microbiome in subjects with irritable bowel syndrome. PMID:25865706
- Irritable Bowel Syndrome and the Small Intestinal Microflora. What Do We Know? PMID:26076568
- Differences of microbiota in small bowel and faeces between irritable bowel syndrome patients and healthy subjects. PMID:26595305
- No difference in small bowel microbiota between patients with irritable bowel syndrome and healthy controls. PMID: 25687743
Low FODMAP Diet
- Food Components and Irritable Bowel Syndrome. PMID:25680668
- Diets that differ in their FODMAP content alter the colonic luminal microenvironment. PMID:25016597
- Randomised clinical trial: gut microbiome biomarkers are associated with clinical response to a low FODMAP diet in children with the irritable bowel syndrome. PMID: 26104013
- Editorial: predicting response to a low FODMAP diet in children - authors' reply. PMID:26278562
- Editorial: predicting response to a low FODMAP diet in children. PMID:26278561
- Clinical response in Mexican patients with irritable bowel syndrome treated with a low diet low in fermentable carbohydrates (FODMAP). PMID:26300323
- Does a low FODMAP diet improve symptoms in Mexican patients with IBS? PMID:26275634
- Low FODMAP diet. PMID:26273081
- Diet low in FODMAPs Reduces Symptoms of Irritable Bowel Syndrome as Well as Traditional Dietary Advice: A Randomized Controlled Trial. PMID:26255043
- Does a low FODMAP diet help IBS? PMID:26251411
- Randomised clinical trial: gut microbiome biomarkers are associated with clinical response to a low FODMAP diet in children with the irritable bowel syndrome. PMID:26104013
- Sensitivity to wheat, gluten and FODMAPs in IBS: facts or fiction? PMID:26078292
- Does a diet low in FODMAPs reduce symptoms associated with functional gastrointestinal disorders? A comprehensive systematic review and meta-analysis. PMID:25982757
- [Insufficient evidence of the effect of the low FODMAP diet on irritable bowel syndrome]. PMID:25922242
- Systematic review: dietary fibre and FODMAP-restricted diet in the management of constipation and irritable bowel syndrome. PMID:25903636
- Clinical effectiveness and economic costs of group versus one-to-one education for short-chain fermentable carbohydrate restriction (low FODMAP diet) in the management of irritable bowel syndrome. PMID:25871564
- The Science, Evidence, and Practice of Dietary Interventions in Irritable Bowel Syndrome. PMID:25769411
- Dietary treatment of irritable bowel syndrome. PMID:25601299
- The low-FODMAP diet for irritable bowel syndrome: Lights and shadows. PMID:26548734
If you value this website, consider supporting the free information provided on siboinfo.com and it's newsletter, which helps SIBO sufferers world wide.
Site author: Dr Allison Siebecker
